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Perioperative cardiac events continue to represent a significant cause of
morbidity in patients undergoing noncardiac surgery. The evaluation ofthehigh
risk patient should begin with an assessment of the probability of coronary
artery disease and exercise tolerance. Decisions to undergo further evaluation,
including noninvasive testing, should be based upon the perioperative morbid-
ity and mortality rate for theplanned surgical procedure. Inpatients with signif-
icant coronary artery stenoses and a high probability of perioperative cardiac
morbidity, coronary artery bypass grafting, percutaneous transluminal coronary
angioplasty, and preoperative optimization of hemodynamics in an intensive
care unit have all been advocated as means ofreducing risk.
As our population ages, an increasing proportion ofthe patients who present for non-
cardiac surgery have either overt or asymptomatic cardiovascular disease. Based upon
demographic data, it is estimated that this represents approximately 7 million of the 25
million Americans anesthestized annually [1, 2].
This review will emphasize pre- and post-operative evaluation of patients with car-
diovascular disease. The areas to be covered include: (1) coronary artery disease
(CAD)b, (2) risk factors for CAD, (3) congestive heart failure (CHF), (4) preoperative
cardiovascular testing strategies, and (5) perioperative interventions forpatients-at-risk.
The assessment of the high risk surgical patient should be approached in an orderly
manner. It is important to evaluate the patient for the probability of CAD. The patient
may present with definite CAD or may have a high probability ofCAD by virtue oftheir
risk factors. For example, patients with angina or a previous MI have definite CAD.
Patients with diabetes, hypertension, advanced age, tobacco use, hypercholesterolemia, or
peripheral vascular disease are atrisk forCAD, with the probability ofCAD afunction of
the interaction ofeach risk factor. It is next important of assess ventricular function. The
simplest way is to determine the patient's exercise tolerance. Finally, the decision to per-
form further evaluation should be based upon the perioperative morbidity and mortality
rate for the planned surgical procedure.
CORONARY ARTERY DISEASE
Coronary artery disease, as manifested by a prior myocardial infarction or angina, is
estimated to be present in over 6 million Americans [3]. A history ofcoronary artery dis-
ease has been associated with an increased risk ofperioperative morbidity or mortality in
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multiple studies [4-8]. In assessing the probability and extent of coronary artery disease,
the starting point begins with an extensive history. Patients with unstable angina have an
active process occurring at the point ofan atherosclerotic plaque, and should not undergo
surgery unless delay and further medical or surgical treatment of the coronary artery dis-
ease is impossible [8]. In the patient with stable classic anginal pain, the probability of
coronary artery disease and myocardium-at-risk approaches 100%. However, the proba-
bility that the disease will progress or result in a MI varies. The patient with a prior MI
without symptoms may have extensive coronary artery disease, but may also have
infarcted the only area of myocardium-at-risk. In asymptomatic patients, the probability
ofcoronary artery disease depends upon the presence ofco-existing risk factors.
Traditionally, an MI within six months of surgery has been associated with a high
rate ofreinfarction in multiple studies [6,9, 10]. Rao etal. [9], and morerecently Shah et
al. [11] from the same institution, demonstrated that the rate of reinfarction has been
reduced in the modem era. They attributed the improved outcome to the use of beta-
blockade, invasive monitoring, and prolonged Intensive CareUnit stays. Although the six
month interval continues to be quoted in the anesthetic literature, significant changes in
the care of the acute myocardial infarction patient may change the degree of risk.
Patients are undergoing coronary angioplasty or receiving thrombolytics, thereby chang-
ing the characteristics of the coronary circulation and the extent of the myocardium-at-
risk. We believe that the perioperative risk of a patient with a recent MI is not simply a
function of the interval between the MI and surgery, but requires further stratification
based upon the ongoing extentofmyocardium-at-risk.
In assessing the extent of coronary artery disease, it is important to determine the
patient's exercise tolerance. Patients with an extensive exercise tolerance clinically
demonstrate good myocardial reserve. In contrast, the patients who develop dyspnea with
exertion have a high probability ofextensive coronary artery disease and limited myocar-
dial reserve. These patients do not require further testing to confirm the diagnosis of
CAD unless further interventions such as coronary artery bypass grafting areplanned.
RISK FACTORS FOR CORONARY ARTERY DISEASE
As noted above, there are several risk factors which place the patient at a higher
probability of coronary artery disease [6, 12]. Diabetes has traditionally been one of the
strongest risk factors for atherosclerotic disease, as well as leading to the silent nature of
the disease. Recent studies have suggested that signs of autonomic dysfunction, rather
than peripheral neuropathy, is the best predictor of silent myocardial ischemia [13]. In
addition, patients with autonomic dysfunction may have exaggerated blood pressure
response to anesthetic agents. Therefore, a simple assessment of the autonomic function
of the diabetic patientprovides important information for theirperioperative care.
HYPERTENSION
Of the cardiovascular diseases, hypertension is the most prevalent, affecting more
than 59 million patients. Forty percent ofpatients who are aware that they have hyperten-
sion, are either untreated or inadequately managed with pharmacologic therapy [14].
Therefore, a large percentage of patients with hypertension can present for preoperative
anesthesia evaluation with poor control of their disease. Hypertension is also an impor-
tant marker as a risk factor for congestive heart failure and ischemic heart disease.
Hypertension results in: 1) an increased systemic vascular resistance, 2) decreased
intravascular volume, 3) exaggerated pressor response and 4) edema. The criteria for the
diagnosis of hypertension has recently changed. The newest report from the Joint
National Committee on hypertension presents a new classification schema which includes
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both systolic and diastolic levels [151. Thisrecording format is used to convey the impact
of the cardiovascular risks of higher BP. Most hypertension is essential; in selected
patients as indicated by history, physical examination and baseline laboratory data, a
more extensive workup may reveal a primary and treatable cause of hypertension (e.g.,
renal artery stenosis). Recently, the absence ofcircadian variation in BP has been identi-
fied as a major risk factor in patients with hypertension. Lack of circadian variation is
associated with LVH [16]. The presence of LVH in a patient with essential hypertension
is an important prognostic indicatorofcardiovascular morbidity.
Commonly, hypertension on admission to the hospital is regarded as a "normal"
response to the stress of hospital admission. However, this group of patients may repre-
sent an untreated orinadequately managed subset ofhypertensivepatients. Astudy exam-
ining this problem revealed that these patients generated the highest mean arterial BP
(MAP) in response to laryngoscopy and intubation [17]. In addition, myocardial ischemia
was observed, and 75% of the patients in this group required vasodilator therapy. In con-
trast, those patients with normal admission BP, oradequately treated hypertension, had an
uneventful peri-induction course.
In the perioperative period, uncontrolled or poorly controlled hypertension is associ-
ated with an increased incidence of ischemia, myocardial infarction, dysrhythmias, and
stroke [18]. Adequate preoperative treatment is associated with a reduced incidence of
serious cardiovascular complications. Anti-hypertensive therapy has a salutary effect with
regard to the anesthetic management ofhypertensive patients. Even a single dose ofbeta
antagonist administered 90 min. prior to induction of anesthesia results in a significant
reduction in the incidence of intraoperative hypertension and myocardial ischemia, as
well as postoperative cardiac morbidity [19,20].
Current consensus when managing hypertensive patients suggests continuation of
antihypertensive maintenance of drug therapy throughout the perioperative period; this
includes maintenance of the patient's routine anti-hypertensive medication with the anes-
thesia premedication. The recent approval of intravenous diltiazem offers an agent with
excellent anti-ischemic properties to the choices forintraoperative management [21].
CONGESTIVE HEART FAILURE
The impact of CHF on perioperative morbidity and mortality is often minimized,
even though it was associated with the highest risk ofmorbidity in the Goldman Cardiac
Risk Index [6]. Currently, 2.3 million Americans have CHF, with 400,000 added each
year. The mortality rate of CHF is between 15-60% with 200,000 deaths each year. The
etiology of CHF is multifactorial and may be the result of a cardiomyopathy, diastolic
dysfunction, or ischemic left ventricular dysfunction. The first two etiologies may lead to
a reversible process during theperioperativeperiod, and careful fluid managementis crit-
ical in these patients. If the etiology of CHF is myocardial ischemia, then irreversible
myocardial necrosis and cardiac pump failure is a significant possibility. Therefore, the
extent ofmyocardium-at-risk forischemia should be discerned in thepatientwith CHF.
PREOPERATIVE TESTING STRATEGIES
The decision to perform further preoperative testing depends upon the reason for the
testing. Although the definitive diagnosis of coronary artery disease is potentially useful
in all high risk patients, the costof such routine testing would be prohibitive and be asso-
ciated with somerisk. Therefore, testing must be reserved for thosepatients in whom care
would be modified based upon the test results.
The risk of developing perioperative myocardial ischemia and cardiac morbidity
should be used as a starting point in any decision algorithm [1]. For example, procedures
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such as transurethral resection of the prostate or minor orthopedic procedures are associ-
ated with a low incidence of cardiac morbidity [22]. Except for patients with unstable
angina, no supplemental cardiovascular tests are required. In contrast, patients undergo-
ing high aortic cross-clamp procedures have an extremely high incidence ofischemia and
cardiac morbidity and cardiovascular testing would be useful in all patients with clinical
risk factors [23].
Multiple testing modalities have been suggested as part of the preoperative evalua-
tion. The predictive value of a test in a particular patient is a function of the sensitivity
and specificity of the test, and the pre-test probability of disease [24]. In patients with a
very high pre-test probability of disease, noninvasive testing adds very little additional
information. In such patients, coronary angiography may be the appropriate first test.
Exercise stress testing is frequently the first test in the diagnostic evaluation ofcoro-
nary artery disease. An ECG stress test progressively increases myocardial work with
graded exercise. Indicators of ischemia include development of angina, ECG changes
(e.g, ST segment deviation, the appearance ofdysrhythmias, conduction defects, etc.) and
hemodynamic abnormalities. The presence of signs of left ventricular dysfunction, i.e.,
hypotension or dyspnea, should alert the clinician to the increased risk of perioperative
cardiovascular dysfunction. In addition, the exercise tolerance the patient demonstrates is
an important determinant of risk. McPhail et al. [25] demonstrated that the inability to
achieve 85% of peak maximal heart rate is the best predictor of subsequent cardiac mor-
bidity in high risk patients undergoing arterial reconstruction.
Many high risk patients have stress tests in accordance with practice guidelines
developed by the American College of Cardiology and American Heart Association.
They recommend symptom limited exercise testing or cardiac catheterization for almost
all patients within 6-8 weeks following an acute MI [26]. However, the ECG exercise
test is of limited value as a screening device in the asymptomatic population. Finally,
ECG stress testing data should be viewed with caution since sensitivity and specificity
will be different in men and women.
In patients with pre-existing ECG abnormalities, or when the result of the ECG stress
test is ambiguous or yields an unexpected result, nuclear imaging can be added to exer-
cise testing. Traditionally, planar imaging combined with thallium-201 has been used.
More recent studies use SPECT (single photon emission computerized tomography)
imaging combined with technetium-99, which provides better localization and quantiza-
tion of the perfusion defect. At rest , a severe coronary stenosis (> 90%) must be present
for the thallium test to be positive. "Cold" spots or perfusion defects appear 30-60 min.
post-radioisotope injection. A period ofredistribution occurs at 2-4 hrs. A repeat image
is ordered at 4 hrs. Cold spots that are present at 1 hr but disappear at 4 hrs (reversible)
indicate areas at risk for myocardial ischemia. Although defects in the 1-hr and 4-hr tests
were thought to indicate infarcted tissue, more recent studies suggest that a significant
percentage ofthese persistent defects represent severe ischemia [27].
A significant number of high risk patients with CAD cannot perform an exercise
stress test. In these individuals, pharmacologic stress testing is employed. These tests rely
on decreasing myocardial oxygen supply through coronary blood flow redistribution
(dipyridamole); or, increasing myocardial oxygen consumption (dobutamine) [28].
Dipyridamole is a coronary vasodilator administered to patients who cannot perform
exercise on a treadmill due to peripheral vascular disease. The dipyridamole thallium test
(DTI) not only supplies important diagnostic information, but also has been shown to
have significant prognostic capabilities in selected subsets of surgical patients [29-35].
However, a recent report has urged caution in applying the results of the test to surgical
patients. Mangano et al. [36] were unable to demonstrate a significant predictive value of
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a positive scan when studied in consecutive vascular surgery patients with the anesthetic
care team unaware ofthe results. An accompanying editorial questions their methodology
and study endpoints. One group suggests that DTI is of limited value for single vessel
coronary disease (left main or right coronary arteries) or proximal triple vessel disease
[37]. More recent studies suggest that improvements in protocol (repeat thallium injec-
tion) and quantitative measurements ofredistribution will improve thepredictive value of
the test [38, 39]. Additionally, the presence ofincreased lung uptake is a sign ofleft ven-
tricular dysfunction and identifies those patients at increased risk for subsequent morbidi-
ty.
Ambulatory electrocardiography (AECG), by use of a Holter monitor type device,
allows ECG detection of symptomatic ischemic events (angina) as well those that are
clinically silent (no angina). Advocates of this technology claim it is more useful than
current diagnostic tests both for diagnosis and risk assessment [40-43]. In one recent
study comparing DTI and AECG, the positive and negative predictive values ofthe tests
were similar [44]. The significantly lower costofAECG monitoring makes it very attrac-
tive in risk stratification. However, an American Heart Association task force evaluating
this technology stated that more data is required before AECG becomes an acceptable
part ofroutine diagnostic test methods forCAD [45].
More recent attention has focused on the assessment of ventricular dysfunction.
Although a very poor ejection fraction is associated with an increased risk of periopera-
tive morbidity, there is considerable controversy regarding the predictive value of a mod-
erate ejection fraction [34, 46, 47]. Increasing evidence suggests that it is the dynamic
response to stress that is the best predictor of outcome. In patients who are able to exer-
cise, a good exercise tolerance is associated with good outcomes irrespective of the risk
for ischemia. Several recent studies have reported the best positive and negative predic-
tive values in the literature using pharmacologic echocardiography stress testing [48-52].
Further studies are required to confirm these new findings.
In choosing the appropriate test, cost-benefit analysis must be considered. Table 1
lists representative sensitivities, specificities and cost ofthe more commonly ordered car-
diac diagnostic tests. Additionally, the predictive value ofthe test for the individual insti-
tution should be determined, since notall tests are performed as well by all laboratories.
Appropriate sequencing of diagnostic tests not only improves sensitivity and speci-
ficity for the diagnosis ofCAD, but also improves risk stratification. From the preceding
discussion, it is apparent that patients can be divided into three risk groups: low, interme-
diate and high. In a group ofpatients (n = 200) undergoing major vascular surgery, Eagle
et al. [53] described a low risk group who had no clinical variables (e.g., angina, diabetes,
Q waves on ECG, etc) for the presence of CAD [50]. Only 3% (2/64) sustained a post-
Table 1. Representative sensitivities, specificities, and relative costs ofcardiac diagnostic tests.
Test Sensitivity(%) Specificity(%) Cost($)
AMBULATORY ECG (24HR) 70 85 280
ECG STRESS TEST 65 80 450
STRESS ECHO 80 85 600
THALLIUM (planar) 90 80 1200
THALLIUM (SPECT) 90 90 1200
DIPYRIDAMOLE THALLIUM 90 90 1200
CARDIAC CATHETERIZATION 95 95 2500
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Figure 1. Algorithm for the use of cardiac diagnostic tests. AECG = ambulatory ECG. See
text for details. Reproduced with permission. Barash, P. G. Preoperative evaluation of the cardiac
patient for noncardiac surgery. Clinical Anesthesia Update Series. Vol. I-1. J.B. Lippincott
Publisher, Philadelphia, 1990.
operative ischemic event. In contrast, the high risk group (three or more clinical factors),
50% (10/20) had clinically significant postoperative cardiac morbidity. A majority ofthe
patients (n = 116) had one or twoclinical variablespresentandwereassigned to the inter-
mediate risk group. On the basis of the presence or absence ofthallium redistribution on
their dipyridamole thallium test, this group could be further subdivided into low (n = 64)
and high risk (n = 54) subsets. Only 3% (2/64) patients without thallium redistribution
had a post operative cardiac event. In comparison, those with thallium redistribution had
30% (16/54) postoperative cardiac event rate. The authors concluded that preoperative
DTI, helps stratify those patients who were determined to be at intermediate riskby clini-
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PROPOSED ALGORITHM FOR PATIENTS UNDERGOING SURGERY ASSOCIATED
WITH A HIGH RISK OF PERIOPERATIVE MYOCARDIAL ISCHEMIA
HISTORY
PHYSICAL EXAM
ECG
DOCUMENTED AT RISK FOR
CORONARY ARTERY DISEASE CORONARY ARTERY DISEASE
PRIOR Ml PRIOR Ml CHRONIC 0-WAVE <6WK QWAVE >6WK STABLE NON-Q <6 MON NON-Q 6MON ANGINA
GOOD POOR GOOD POOR GOOD POOR
EXERCISE EXERCISE EXERCISE EXERCISE EXERCISE EXERCISE
TOLERANCE TOLERANCE TOLERANCE TOLERANCE TOLERANCE TOLERANCE
CORONARY EXERCISE IPYRIDAMOLE EXERCISE CORONARY AMBULATORY DIPYRIDAMOLE
ANGIOGRAPHY THALLIUM HALLIUM THALLIUM ANGIOGRAPHY ECG THALLIUM
TESTING ESTING TESTING OR TESTING
SURGERY
Figure 2. Algorithm for patients undergoing surgical procedures with a HIGH risk ofperlop-
erative myocardial lschemia, e.g., resection of an abdominal aortic aneurysm. (Reproduced
with permission Reference 1).
cal evaluation. Further, and perhaps more important, that for nearly half the patients in
their series, clinical information alone predicted risk (high and low risk groups) and the
use ofthe DPI was unnecessary.
Using this guided approach to the ordering of cardiodiagnostic tests, an algorithm
can be developed to aid the clinician (Figure 1). More extensive testing implies that an
operation may be delayed, canceled or postponed based on the test results. For example,
consideration given to coronary revascularization or coronary angioplasty before a non-
cardiac surgical procedure must include factoring the incremental risk of these proce-
dures.
In contrast to the more traditional approach, Fleisher and Barash [1] proposed a
method of stratifying risk based on the impact of the surgical procedure to increase peri-
operative ischemia, as described previously. This approach is based upon the concept that
a certain threshold of cardiac morbidity must occur before a test has any value. If the
prevalence of disease in the population is high, morbidity is low, and perioperative care
would not be altered by a more definitive diagnosis ofCAD, testing would add minimal
or no benefit and would be associated with cost. After allocating the patient to a given
risk group based on surgical procedure, the workup is performed on the basis ofthe pres-
ence ofdocumented CAD, e.g., those at high risk for CAD and those with no or low risk
of CAD (Figures 2-3 ). They suggest that the need for a confirmatory diagnosis ofcoro-
nary artery disease, i.e., further testing, depends upon the perioperative morbidity and
mortality rate for the planned procedure. If care will not be modified based upon the
results ofany test, then furtherevaluation may not have great utility but would add signif-
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PROPOSED ALGORITHM FOR PATIENTS UNDERGOING SURGERY ASSOCIATED
WITH A LOWTO MODERATERISK OF PERIOPERATIVE MYOCARDIAL ISCHEMIA
Figure 3. Algorithm for patients undergoing surgical procedures with a LOW-MODERATE
risk of perioperative myocardial lschemia, e.g., peripheral procedures. (Reproduced with per-
mission Reference 1)
icant costs. Eagle and Boucher [54] suggest that patient subsets with expected periopera-
tive cardiovascular event rate greater that 15% should be more extensively tested. Those
subsets who exhibit amorbidity rate less than 5% do notrequire furtherscreening.
PERIOPERATIVE INTERVENTIONS
Coronary revascularization prior to noncardiac surgery in patients with significant
coronary artery disease has been suggested for over a decade [55]. To date, however, a
randomized trial to determine the benefit of revascularization has not been performed.
Hertzer et al. [56, 57] demonstrated that younger, nondiabetic patients who had CABG
prior to major vascular surgery had improved long-term survival compared to a similar
surgical cohort with documented coronary artery disease who did not undergo coronary
revascularization. However, the decision to undergo CABG was not randomized, which
represents a strong source of bias. Vascular surgery patients, the group with the greatest
potential benefit from revascularization, also have a high morbidity and mortality from
CABG. Therefore, only selectedpatients may accrueasignificantbenefit.
More recently, PTCA has been proposed prior to noncardiac surgery. Huber et al.
[58] and Gottlieb [59] have both reported retrospective series demonstrating low periop-
erative cardiac morbidity rates in patients withPTCAprior to vascular surgery. The lower
morbidity and mortality rates forPTCA may provide benefit with minimal risk.
A third alternative is to admit the patient to the ICU prior to noncardiac surgery and
perform a "preoperative tune." Berlauk et al. [60] designed care algorithms to optimize
hemodynamics using a pulmonary artery catheter prior to infrainguinal bypass surgery. In
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arandomized clinical trial, they demonstrated a significantly lower morbidity and mortal-
ity in patients who had a "tune" either in the ICU or in the induction area when compared
to patients who did not have a "tune" or pulmonary artery catheterplaced unless clinical-
ly indicated. Further studies are needed toconfmn theirfindings.
In summary, preoperative evaluation continues to be an important component of
anesthetic practice. Once a database is established, the ideal method of intervention to
reduce risk mustbalance thebenefits andrisks.
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